Westlake’s Kythera sells for $2.1 billion



An Irish-based company is buying Kythera Biopharmaceuticals (NASDAQ: KYTH) of Westlake Village in a $2.1-billion cash and stock transaction announced June 17. The deal allows Allergan (NYSE: AGN), a global pharmaceutical company headquartered in Dublin, to gain control of Kythera’s newly marketed treatment for reduction of the human double chin. Kythera’s Kybella injection is the first non-surgical treatment for double chins to receive FDA approval. Kythera is also seeking approval for the trea...

Oops! An active online subscription is required to access this content.

Please login below or Subscribe today!